Creative Touch Permanent Makeup and Aesthetics

Mounjaro is a dual agonist: it activates both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors simultaneously. This produces a more powerful appetite suppression than GLP-1 monotherapy alone. For most people in the early weeks, eating becomes genuinely difficult. Food sits heavily. You reach fullness after a few bites. Meals that used to be unremarkable now feel like an effort.

This is the treatment working. But there’s a consequence that doesn’t always get explained clearly: when your total food intake drops sharply, your total energy intake drops with it. And if you’re not being strategic about what you eat within those smaller portions, you can find yourself in a significant caloric and nutritional deficit before you’ve even noticed.

Your brain is metabolically expensive. Your muscles are metabolically expensive. Your immune system doesn’t switch off. When energy supply drops faster than your body can adapt, you feel it, and you feel it first as fatigue.

The particular cruelty of this mechanism is that it compounds. Eating less means eating fewer B vitamins, less magnesium, less iron, less of everything your cells need to produce ATP (the cell’s primary energy currency). Hair follicles and energy metabolism have the same upstream problem: insufficient nutritional raw material. This is why the protein targets we recommend in our article on Mounjaro and hair loss apply equally here: 1.2–2.0 grams per kilogram of adjusted bodyweight, a target endorsed by a 2025 joint advisory from four professional nutrition and obesity societies. ^[3] Not because protein is magical, but because it’s the macronutrient most likely to be critically low when appetite is suppressed, and without it, your body starts cannibalising the tissues it was trying to protect.

Research from 2025 examining 69 GLP-1 users found that the average daily protein intake was just 77 grams, well below the therapeutic target. Only 43% reached the minimum 1.2g/kg threshold. Just 10% reached 1.6g/kg. These aren’t people making poor choices; they’re people whose appetite has been pharmacologically suppressed, trying their best with the guidance they’ve been given. ^[4]

Timeline: This cause of fatigue is most prominent in weeks 1–8, peaks around dose escalation events, and improves substantially once eating patterns stabilise and nutritional adequacy is restored.

Nausea, vomiting, and diarrhoea are the most common side effects of Mounjaro by a significant margin – affecting 12–17% of users at therapeutic doses (other GI side effects, including constipation, are covered in detail in a separate article). They’re uncomfortable and they pass. But they have a secondary consequence that rarely gets its own paragraph: they make you exhausted.

The mechanism here is partly electrolyte depletion (more on that in the management section), partly disrupted sleep when symptoms hit at night, and partly the simple physical toll of the body managing active GI distress. If you’re vomiting, you’re expending energy. If you’re waking at 2am with nausea, your sleep architecture is disrupted in ways that hit energy levels the following day.

This is an important distinction: some people who believe they’re experiencing “fatigue as a Mounjaro side effect” are actually experiencing fatigue as a downstream consequence of undertreated GI symptoms. The two feel identical, but they have different solutions. Managing nausea proactively, such as eating smaller portions more slowly, avoiding rich or spicy foods, being attentive to dose timing, can resolve what feels like an energy problem.

Timeline: Closely tracks GI symptoms. Tends to be worst in the first four weeks and during dose escalations. Most people find it settles considerably by week six to eight.

This one is more interesting, and it connects to something you might already have noticed in your pre-Mounjaro life.

Many people who start GLP-1 medications are coming from a metabolic baseline characterised by insulin resistance, blood glucose spikes after meals, and the reactive crashes that follow. That pattern creates predictable energy troughs: the post-lunch dip, the 4pm slump, the craving for something sweet in the late afternoon that feels almost like physical need.

If that sounds familiar, there’s a whole other piece of biology at work: the interplay of factors including cortisol rhythms and blood sugar cycling, and why carbohydrate cravings peak specifically in the mid-to-late afternoon. We’ve written about this in detail in our article on why you crave carbs at 4pm, and it’s worth reading alongside this one, because the two processes interact directly.

What Mounjaro does to this pattern is disrupt it, in a productive but initially disorienting way. As insulin sensitivity improves and blood glucose becomes more stable, the dramatic peaks and troughs flatten. ^[5] This is ultimately a good thing. But during the transition, the body has to recalibrate its energy regulation. Cells that have been running on a cycle of high glucose followed by reactive insulin responses are now asked to burn fuel more steadily and efficiently. That adjustment takes time, and during the adjustment period, the signals that used to tell your body “it’s time to feel alert” or “it’s time to feel energised” are temporarily out of calibration.

Patients also on other diabetes medications (sulphonylureas in particular) face an additional consideration here: the improved insulin sensitivity that Mounjaro produces can create hypoglycaemic episodes when combined with medications that force insulin secretion regardless of blood glucose levels. ^[1] Even mild hypoglycaemia produces profound fatigue. If you’re on concurrent diabetes medications and your tiredness is accompanied by shakiness, sweating, or difficulty concentrating, this is a signal worth discussing with your prescriber promptly, not something to manage with a biscuit and a lie-down.

Timeline: Metabolic recalibration fatigue typically follows glucose stability. It tends to reduce as treatment continues and the new metabolic equilibrium becomes the norm, usually by weeks six to twelve.

This one is genuinely underappreciated. GI symptoms at night, nausea particularly, may affect sleep quality even when they don’t wake you fully. You may feel like you slept eight hours whilst actually having spent significant time in lighter, less restorative sleep stages.

But here’s the counterintuitive part. The full-picture story of Mounjaro and sleep is not a negative one. The SURMOUNT- OSA trials, which assessed tirzepatide specifically in patients with obesity-related obstructive sleep apnoea, ^[6] found that over the course of fifty-two weeks, patients reported significant improvements in daytime sleepiness, sleep-related functioning, and overall sleep quality. As weight falls and upper airway anatomy improves, sleep becomes more restorative. The early disruption gives way to better sleep than many patients have had in years.

If you have undiagnosed sleep apnoea (common in people with obesity, often unrecognised), Mounjaro may be the treatment that finally begins to address the underlying cause of fatigue you’ve been living with for a long time without understanding why.

Timeline: Sleep disruption from GI symptoms resolves as those symptoms settle. Sleep quality improvements from weight loss typically become noticeable from week twelve onwards, with more significant benefits accumulating over six to twelve months.

Excess adipose tissue is not passive storage. It’s metabolically active, producing inflammatory signalling molecules including TNF-alpha, interleukin-6, and C-reactive protein. ^[7] This chronic low-grade inflammation has a direct effect on energy: it’s part of why people with obesity frequently experience fatigue that has no obvious immediate cause. The immune system is essentially running in background mode, quietly consuming energy and disrupting cellular function.

As Mounjaro reduces body fat, these inflammatory markers fall. ^[6] The fatigue that resolves isn’t always the fatigue the medication caused. Sometimes it’s the fatigue the patient arrived with, finally being addressed. This reframe matters, because it means some of what people experience as “more energy on Mounjaro” isn’t a drug effect at all. It’s the simple consequence of carrying less inflammatory load.

One of the most persistent fears about GLP-1 medications is that they cause muscle wasting, and that this wasting causes weakness, reduced physical capacity, and fatigue. This fear has been amplified by body composition data from large trials showing that a significant percentage of weight loss comes from lean body mass.

The most rigorous primary data available now suggests this fear has been overstated. Langer et al. (2026), published in Cell Reports Medicine, conducted four pre-clinical studies and a clinical trial specifically examining whether GLP-1 medications cause disproportionate muscle loss or functional impairment. Their findings are clear: absolute muscle mass shows a small decrease, but relative muscle mass (muscle as a proportion of bodyweight) improves in every study, across every drug tested (semaglutide, tirzepatide, and survodutide). ^[8] In the Langer study’s animal models, the lean tissue that responded most rapidly wasn’t skeletal muscle, it was liver mass. If this pattern holds in humans, it would mean that the ‘lean mass loss’ figures reported in large trials significantly overstate true muscle loss, since standard body composition scans cannot separate liver from muscle within lean mass. This is a plausible hypothesis with strong pre-clinical support, but direct human confirmation is still needed.

In the functional tests – treadmill performance, grip strength, force-frequency testing, in vivo contractility – the direction was consistently favourable. Mice treated with semaglutide achieved running performance comparable to lean controls, significantly outperforming untreated obese mice. Relative grip strength improved. Fatigue resistance in repeated contractility testing improved. The clinical trial component, a proof-of-concept study of ten patients, found that maximum voluntary knee extension force and hand grip strength were unchanged after twelve weeks of treatment, despite small decreases in absolute muscle cross-sectional area.

The practical implication: if you’re tired on Mounjaro, muscle loss is very unlikely to be the cause. Physical capacity is maintained as treatment continues, and pre-clinical models show consistent improvement; a direction the preliminary human data (n=10, 12 weeks) does not contradict.

This is perhaps the most fascinating piece of the story, and it comes from the proteomics arm of the Langer et al. paper. ^[8] When researchers compared the skeletal muscle protein profiles of semaglutide-treated mice with pair-fed controls (mice eating exactly the same amount, just without the drug), they found striking differences in mitochondrial protein expression. GLP-1RA treatment upregulated mitochondrial proteins involved in oxidative phosphorylation; the process by which cells generate ATP from oxygen. SIRT5, COX5A, NDUFB8, UQCRB: these are proteins associated with efficient cellular energy production.

The fact that the comparator group was calorically matched confirms this is a drug effect, not a starvation response. The mitochondrial changes are driven by GLP-1 receptor activation itself, independent of how much the animals ate. It suggests that GLP-1 receptor agonists don’t just produce weight loss through appetite suppression. They appear to influence muscle cell energy metabolism through mechanisms beyond caloric restriction alone. The implication for long-term energy levels is positive: the cells responsible for physical activity are being primed to produce and use energy more efficiently.

From the same paper’s pre-clinical proteomics analysis, skeletal muscle from semaglutide-treated mice showed increased expression of proteins involved in oxidative phosphorylation – SIRT5, COX5A, NDUFB8, and UQCRB – compared to pair-fed controls eating identical amounts. This suggests GLP-1 receptor agonists may influence muscle energy metabolism through pathways independent of caloric restriction alone, though how this occurs is not yet understood, and whether it translates to measurable improvements in human energy production remains to be established. The direction of the evidence points toward improving cellular energy production – not depleting it.

Put all of this together and the summary is this: early fatigue on Mounjaro is real, common, and has identifiable causes; nearly all of them temporary. The trajectory beyond the adjustment period consistently points toward improved energy, not worse. Reduced inflammation, better sleep quality, improved physical capacity, enhanced mitochondrial efficiency, and the simple benefit of carrying less weight all compound over time.

Most people who ask “does Mounjaro make you tired?” are in their first eight weeks. They deserve to know that the story doesn’t end there.

Not because protein is uniquely magical for energy, but because it’s the nutrient most likely to be critically deficient when appetite is suppressed, and its deficiency has the most immediate consequences.

Aim for 1.2–2.0 grams per kilogram of your adjusted bodyweight daily. ^[3] If you weigh 90kg, that’s a minimum of 108 grams, ideally 135–180 grams. This sounds like a lot, and for most people on Mounjaro it is. The 2025 research found that only 43% of GLP-1 users even reached the minimum threshold. ^[4]

Practical ways to close the gap when food feels like an effort:

• Protein before anything else on the plate. When you only have capacity for a few bites before fullness sets in, make those bites count. Chicken, fish, eggs, Greek yogurt, or cottage cheese before any carbohydrate.
• Liquid protein is your friend. A quality protein shake will often go down easily even when solid food feels impossible. This isn’t cheating – it’s being smart about your physiology.
• Distribute across five or six small occasions. A 30g protein target at each meal is more achievable than trying to eat a large protein-rich meal twice a day.
• Track for at least the first three weeks. Almost everyone significantly overestimates their protein intake without measurement. The numbers are usually humbling.

“Stay hydrated” is advice so universal it’s lost most of its meaning. The specific issue on Mounjaro is that GI side effects deplete electrolytes – sodium, potassium, magnesium – and plain water doesn’t replace them. If you’re experiencing fatigue alongside any of the following: muscle cramps, headaches, brain fog, or an unexplained heavy feeling, electrolyte imbalance is a plausible culprit.

An electrolyte supplement is worth considering – look for one that goes beyond sodium to include potassium and magnesium, as these are the electrolytes most commonly depleted by GI losses. A 2025 multi-society advisory on nutritional priorities during GLP-1 therapy lists magnesium as a specific nutrient of concern and recommends magnesium supplementation ^[3] – making it low-risk and worth trying before assuming the fatigue is simply the medication.

This is practical guidance that rarely appears in patient-facing content. The 24–72 hours after injection tend to be when GI side effects and the associated fatigue are at their most prominent for people who experience them. If your schedule allows, choosing an injection day that places the worst of it on lower-demand days – a Friday injection meaning the rough patch falls on a weekend, for example – can make the early weeks significantly more manageable. We cover the full reasoning behind this in our guide to Mounjaro injection timing.

There’s a tendency to treat early Mounjaro fatigue as a weakness to push through. For most people, it isn’t – it’s an appropriate physiological response to a significant metabolic shift. Pushing hard on exercise during the worst of the GI symptoms period is counterproductive, and rest during this phase isn’t failure.

That said, this period has a natural end. Once GI symptoms have settled – usually by weeks four to six for most people – gentle movement genuinely helps. Short walks improve insulin sensitivity, support mitochondrial health, and regulate the cortisol rhythms that affect energy throughout the day. ^[8] The goal isn’t high-intensity exercise; it’s regular, comfortable movement that tells your metabolic system that physical capacity is expected and needed.

If you’re past week eight, GI symptoms have largely resolved, you’re hitting your protein targets – and you’re still exhausted – don’t assume it will sort itself out. Get blood work done. The specific tests worth requesting:

• Full iron studies ( ferritin, serum iron, TIBC, transferrin saturation) – ferritin below 30 µg/L is likely causing fatigue directly
• Vitamin B12 and folate
• Vitamin D (25-hydroxyvitamin D)
• Full thyroid panel (TSH, free T4, free T3)
• Full blood count

These deficiencies are common in the general population, more common in people with obesity, and more common still in people with significantly reduced food intake. They won’t resolve by themselves. And a ferritin of 15 µg/L will cause profound, persistent fatigue regardless of how well everything else is managed.